DangER: protein ovERload. Targeting protein degradation to treat myelomaARONSON, Lauren I; DAVIES, Faith E.Haematologica (Roma). 2012, Vol 97, Num 8, pp 1119-1130, issn 0390-6078, 12 p.Article

The potential role of epigenetic therapy in multiple myelomaSMITH, Emma M; BOYD, Kevin; DAVIES, Faith E et al.British journal of haematology. 2010, Vol 148, Num 5, pp 702-713, issn 0007-1048, 12 p.Article

Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cellsBRITO, Jose L. R; DAVIES, Faith E; GONZALEZ, David et al.Journal of immunological methods. 2008, Vol 333, Num 1-2, pp 147-155, issn 0022-1759, 9 p.Article

Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to CabozantinibGRAHAM, Timothy J; BOX, Gary; ROBINSON, Simon P et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 4, issn 0027-8874, 1.1-1.10Article

Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myelomaGREY-DAVIES, Elisabeth; BOSWORTH, Jennifer L; BOYD, Kevin D et al.British journal of haematology. 2012, Vol 156, Num 4, pp 552-555, issn 0007-1048, 4 p.Article

Mapping of Chromosome 1 p Deletions in Myeloma Identifies FAM46C at 1 p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse SurvivalBOYD, Kevin D; ROSS, Fiona M; CHILD, J. Anthony et al.Clinical cancer research (Print). 2011, Vol 17, Num 24, pp 7776-7784, issn 1078-0432, 9 p.Article

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatmentsBAGRATUNI, Tina; PING WU; DAVIES, Faith E et al.Blood. 2010, Vol 116, Num 2, pp 250-253, issn 0006-4971, 4 p.Article

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsMORGAN, Gareth J; DAVIES, Faith E; DRAYSON, Mark T et al.Haematologica (Roma). 2012, Vol 97, Num 3, pp 442-450, issn 0390-6078, 9 p.Article

Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in MyelomaMITSIADES, Constantine S; DAVIES, Faith E; LAUBACH, Jacob P et al.Journal of clinical oncology. 2011, Vol 29, Num 14, pp 1916-1923, issn 0732-183X, 8 p.Article

Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and OutcomeDICKENS, Nicholas J; WALKER, Brian A; ROSS, Fiona M et al.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1856-1864, issn 1078-0432, 9 p.Article

Deletions of CDKN2C in Multiple Myeloma : Biological and Clinical ImplicationsLEONE, Paola E; WALKER, Brian A; GONZALEZ, David et al.Clinical cancer research (Print). 2008, Vol 14, Num 19, pp 6033-6041, issn 1078-0432, 9 p.Article

A global expression-based analysis of the consequences of the t(4;14) translocation in myelomaDRING, Ann M; DAVIES, Faith E; MUNSHI, Nikhil C et al.Clinical cancer research. 2004, Vol 10, Num 17, pp 5692-5701, issn 1078-0432, 10 p.Article

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapyRAWSTRON, Andy C; KENNEDY, Ben; HILLMEN, Peter et al.Blood. 2001, Vol 98, Num 1, pp 29-35, issn 0006-4971Article

The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cellsRAWSTRON, Andy C; FENTON, James A. L; JACK, Andrew S et al.Blood. 2000, Vol 96, Num 12, pp 3880-3886, issn 0006-4971Article

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationMORGAN, Gareth J; DAVIES, Faith E; RODDIE, Huw et al.Blood. 2011, Vol 118, Num 5, pp 1231-1238, issn 0006-4971, 8 p.Article

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II studySCHEY, Stephen A; MORGAN, Gareth J; RAMASAMY, Karthik et al.British journal of haematology. 2010, Vol 150, Num 3, pp 326-333, issn 0007-1048, 8 p.Article

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialMORGAN, Gareth J; DAVIES, Faith E; ASHCROFT, A. John et al.Lancet (British edition). 2010, Vol 376, Num 9757, pp 1989-1999, issn 0140-6736, 11 p.Article

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cellsDAVENPORT, Emma L; MOORE, Hannah E; DUNLOP, Alan S et al.Blood. 2007, Vol 110, Num 7, pp 2641-2649, issn 0006-4971, 9 p.Article

Haplotypes in the tumour necrosis factor region and myelomaMORGAN, Gareth J; ADAMSON, Peter J; BIDWELL, Jeffrey L et al.British journal of haematology. 2005, Vol 129, Num 3, pp 358-365, issn 0007-1048, 8 p.Article

Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanismAL FENTON, James; PRATT, Guy; OWEN, Roger G et al.Oncogene (Basingstoke). 2003, Vol 22, Num 7, pp 1103-1113, issn 0950-9232, 11 p.Article

Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myelomaDASGUPTA, Ranjit K; ADAMSON, Peter J; MORGAN, Gareth J et al.Blood. 2003, Vol 102, Num 7, pp 2345-2350, issn 0006-4971, 6 p.Article

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationRAWSTRON, Andy C; DAVIES, Faith E; DASGUPTA, Ranjit et al.Blood. 2002, Vol 100, Num 9, pp 3095-3100, issn 0006-4971, 6 p.Article

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX StudyRAWSTRON, Andy C; CHILD, J. Anthony; ROSS, Fiona M et al.Journal of clinical oncology. 2013, Vol 31, Num 20, pp 2540-2547, issn 0732-183X, 8 p.Article

Common variation at 3p22.1 and 7p15.3 influences multiple myeloma riskBRODERICK, Peter; CHUBB, Daniel; DAVIES, Faith E et al.Nature genetics. 2012, Vol 44, Num 1, pp 58-61, issn 1061-4036, 4 p.Article

Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myelomaRODDAM, Philippa L; ALLAN, James M; DRING, Ann M et al.British journal of haematology. 2010, Vol 149, Num 2, pp 258-262, issn 0007-1048, 5 p.Article